Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1068977-12-7

Post Buying Request

1068977-12-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1068977-12-7 Usage

Compound type

Pyrimidinecarboxylic acid derivative

Substituent group

Methoxyphenyl group

Position of substituent group

Attached to the 2-position of the pyrimidine ring

Structural similarity

Nucleobases

Potential applications

Pharmaceutical (as a drug or drug precursor)

Current status

Pharmacological properties under investigation

Ability

Interact with biological systems

Check Digit Verification of cas no

The CAS Registry Mumber 1068977-12-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,8,9,7 and 7 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1068977-12:
(9*1)+(8*0)+(7*6)+(6*8)+(5*9)+(4*7)+(3*7)+(2*1)+(1*2)=197
197 % 10 = 7
So 1068977-12-7 is a valid CAS Registry Number.

1068977-12-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(2-methoxy-phenyl)-pyrimidine-5-carboxylic acid

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1068977-12-7 SDS

1068977-12-7Downstream Products

1068977-12-7Relevant articles and documents

Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models

Amaradhi, Radhika,Banik, Avijit,Mohammed, Shabber,Patro, Vidyavathi,Rojas, Asheebo,Wang, Wenyi,Motati, Damoder Reddy,Dingledine, Ray,Ganesh, Thota

, p. 1032 - 1050 (2020/03/10)

Activation of prostanoid EP2 receptor exacerbates neuroinflammatory and neurodegenerative pathology in central nervous system diseases such as epilepsy, Alzheimer's disease, and cerebral aneurysms. A selective and brain-permeable EP2 antagonist will be useful to attenuate the inflammatory consequences of EP2 activation and to reduce the severity of these chronic diseases. We recently developed a brain-permeable EP2 antagonist 1 (TG6-10-1), which displayed anti-inflammatory and neuroprotective actions in rodent models of status epilepticus. However, this compound exhibited moderate selectivity to EP2, a short plasma half-life in rodents (1.7 h) and low aqueous solubility (27 μM), limiting its use in animal models of chronic disease. With lead-optimization studies, we have developed several novel EP2 antagonists with improved water solubility, brain penetration, high EP2 potency, and selectivity. These novel inhibitors suppress inflammatory gene expression induced by EP2 receptor activation in a microglial cell line, reinforcing the use of EP2 antagonists as anti-inflammatory agents.

PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS

-

Page/Page column 134-135, (2008/12/04)

This invention is directed to a compound wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1068977-12-7